MPM BioVentures 2014 reports Entrada Therapeutics common stock sale worth $621,585.04
Reuters2026/09/03 23:21- MPM BioVentures 2014, a more-than-10% owner, reported sales of Entrada Therapeutics common stock from Sept. 1-3, 2026.
- Disposed of 86,482 shares at weighted-average prices of USD 7.06, USD 7.19, USD 7.17.
- Indirect beneficial ownership fell to 4,144,952 shares following the Sept. 3 transactions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wells Fargo lowers ON Semiconductor's target price to $95
AI venture capital moves from frenzy to selective! The bubble is being squeezed, and an industry shake-up may be imminent
Venture capital experts indicate that as certain sectors are showing signs of overvaluation, investors should shift their focus to productivity growth in artificial intelligence companies.
The collapse of arbitrage trading boosts the yen's surge, as expectations for a Bank of Japan rate hike continue to rise.
As traders increase their bets on further rate hikes by the Bank of Japan, large-scale unwinding of yen-funded carry trades has driven the yen to its highest level against the US dollar in a month.
Lindian Resources signs 10-year offtake deal with Carester for rare earths output
Crypto prices
More
